NewsBenzingaRezolute Announces Results From Its Ongoing Open-Label Phase 3 upLIFT Study Of Ersodetug In Tumor Hyperinsulinism; Primary Efficacy Endpoint Has Been Achieved Based On Preliminary Results; Topline Results Expected By Mid-December 2026 Rezolute Announces Results From Its Ongoing Open-Label Phase 3 upLIFT Study Of Ersodetug In Tumor Hyperinsulinism; Primary Efficacy Endpoint Has Been Achieved Based On Preliminary Results; Topline Results Expected By Mid-December 2026 Benzinga 2026.11.13 11:20 (GMT+0) Open on Benzinga Other news AECOM Hikes Dividend, Backlog Hits Record $28 Billion Elon Musk Steps in After Jensen Huang Loses X Verification Following Nvidia Exit: ‘Blue Check Coming Back for Free on the House’ Trump Backs Howard Lutnick Amid Nvidia Row, Says Restrictions Could Have Triggered China Showdown: ‘I Understand Both Sides of It’ Nvidia Forms Board Panel for Export-Control Oversight Musk Responds to Jensen Huang's X Account Losing Blue Checkmark and Nvidia Affiliate Badge: Will Restore Blue Check for Free Amazon Cranks Up Its India Clean Energy Investment With Fresh $7 Billion Bet
Elon Musk Steps in After Jensen Huang Loses X Verification Following Nvidia Exit: ‘Blue Check Coming Back for Free on the House’
Trump Backs Howard Lutnick Amid Nvidia Row, Says Restrictions Could Have Triggered China Showdown: ‘I Understand Both Sides of It’
Musk Responds to Jensen Huang's X Account Losing Blue Checkmark and Nvidia Affiliate Badge: Will Restore Blue Check for Free